Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SUVEN

SUVEN LIFE S

HealthcareHealthcare Services₹7513 cr market cap
₹277.10 ▲ +4.31% today As of 19 Nov 2026
52-week low ₹126.6552-week high ₹392.05

-32.2% from the 52-week high · +109.8% above the low

Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

The short version. SUVEN LIFE S reported revenue of ₹1 crore for Sep 2026, up 0.0% from a year earlier. Net profit was ₹-107 crore. Return on equity was -46.7% in Mar 2026. Promoter holding was 65.47% in Sep 2026, down 4.80 points over 8 quarters.

1 · The price

How has the stock traded?

SUVEN LIFE S trades 32.2% below its 52-week high and 109.8% above its 52-week low.

Change over period: —

1M-8.4%
3M-20.1%
6M-1.2%
1Y+48.7%

2 · The business

Is it growing?

Sales, year on year+0.0%

Sep 2026 revenue of ₹1 cr.

Net margin-8922.3%

511.7 pts lower than a year earlier.

3-year growth32.7% profit

Revenue compounded at -1.5% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue14231212
Net profit-107-128-46-102-77-52-44-39
Net margin %-8922.3-3578.7-2999.5-3628.8-8410.6-2759.8-2995.6-2429.8
EPS (₹)-3.78-4.83-1.73-4.48-3.4-2.36-2.02-1.79

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue771214121314664
Net profit-276-161-105-118-122-72-9487
Net margin %-3884.1-2415.1-898.6-873.5-1030.0-535.3-653.613.1
EPS (₹)-10.48-7.37-4.82-5.42-5.59-3.78-4.934.55

3 · The quality

How well does it turn capital into profit?

Return on equity was -46.7% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %-46.7-146.2-38.9-31.5
Return on capital %-46.6-143.9-39.0-31.2
EBITDA margin %-1285.7-882.3-302.9-506.8
Net margin %-1313.1-915.8-320.1-537.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-1.5%-0.2%
Profit CAGR32.7%30.8%
Debt to equity0.00
Interest cover-1750.2x
Current ratio17.69

4 · The owners

Who holds it, and are they adding?

Promoter holding65.47%

Down 4.8 pts over 8 quarters.

Foreign institutions0.46%

Up 0.12 pts over 8 quarters.

Domestic institutions2.17%

Up 1.11 pts over 8 quarters.

Mutual fund schemes11

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter70.2770.2770.2767.3667.3670.1570.0865.47-4.8
FII0.340.250.591.181.070.910.570.46+0.12
DII1.060.010.023.393.394.622.932.17+1.11
Public28.3429.4729.1228.0728.1824.3226.4331.9+3.56

Mutual fund holdings · Oct 2026

11 schemes hold this stock

7 the month before.

  • Motilal Oswal Nifty Microcap 250 Index Fund0.24% of NAV
  • Bandhan BSE Healthcare Index Fund0.12% of NAV
  • Motilal Oswal BSE Healthcare ETF0.12% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • Bandhan Nifty Total Market Index Fund0.01% of NAV
  • Groww Nifty Total Market Index Fund0.01% of NAV
  • Angel One Nifty Total Market ETF0.01% of NAV
  • Mirae Asset Nifty Total Market Index Fund0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SUVEN LIFE S are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SUVEN LIFE S

What is the SUVEN LIFE S share price?

SUVEN LIFE S (SUVEN) last closed at ₹277.10, up 4.31% on the day. Its 52-week range is ₹126.65 to ₹392.05.

What is the market cap of SUVEN LIFE S?

SUVEN LIFE S has a market capitalisation of about ₹7,513 crore.

How are SUVEN LIFE S's latest results?

SUVEN LIFE S reported revenue of ₹1 crore for Sep 2026, up 0.0% from a year earlier. Net profit was ₹-107 crore. Return on equity was -46.7% in Mar 2026. Promoter holding was 65.47% in Sep 2026, down 4.80 points over 8 quarters.

Who owns SUVEN LIFE S?

As of Sep 2026, shareholding was: Promoter 65.47%, FII 0.46%, DII 2.17%, Public 31.9%.

How many mutual funds hold SUVEN LIFE S?

11 mutual fund schemes held SUVEN LIFE S in October 2026. That compares with 7 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 17 Oct 2022 · Rights issue 1:2
  • 14 Feb 2019 · Interim Dividend - Rs. 1.5
  • 06 Feb 2018 · Interim Dividend - Rs. 1.5
  • 08 Feb 2017 · Interim Dividend - Rs. 1
  • 14 Mar 2016 · Special Dividend - Rs. 1
  • 23 Jul 2015 · Dividend - Rs. 0.6

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.